MLYS News
Archived Headlines
- Hypertension biotech Mineralys Therapeutics prices upsized IPO at $16, the high end of the range 02/09/23
- US IPO Week Ahead: IPO market heats up with solar trackers, lidar tech, and hypertension drugs 02/03/23
- Cardiorenal disease biotech Mineralys Therapeutics sets terms for $150 million IPO 02/02/23
- Renaissance Capital's January IPO Market Update 02/01/23
- Eight $100+ million IPO filings jumpstart the pipeline in January 01/31/23
See more
Nearly 80% of the year’s large IPOs are above issue, a positive signal for the fall IPO market
The year's crop of large IPOs is off to a strong start, with nearly 80% currently above issue. As long as these solid returns hold, we expect a decent harvest of public listings in the fall. So far this year, 19 IPOs have raised $100 million or more, outpacing...read more
Updated: Renaissance Capital's 1Q 2023 US IPO Market Review
The IPO Pickup Gets Cut Short Following the US IPO market's slowest year in decades, the first quarter of 2023 continued the trend with 29 IPOs raising just $2.3 billion. Deal flow started at a...read more
Renaissance Capital’s February IPO Market Update
Ten IPOs raised a combined $1.5 billion in February, roughly in line with the 10-year median (10 IPOs, $1.3B). Five issuers raised $100+ million, the most since November 2021, led by solar tracker play Nextracker (NXT; $638mm). The rest of the...read more
US IPO Weekly Recap: February IPO market warms up with 4 large deals
Six IPOs began trading this past week, led by four that raised $100+ million, the most in one week since November 2021. They were joined by two SPACs. Several small deals were unable to price (SODR, INTS, BFRG, NFTG, CWD, NRXS). Upsizing and pricing...read more